AnaptysBio (NASDAQ:ANAB) Stock Rating Reaffirmed by Leerink Partnrs

AnaptysBio (NASDAQ:ANAB)‘s stock had its “outperform” rating reiterated by equities researchers at Leerink Partnrs in a research note issued on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

A number of other brokerages have also commented on ANAB. Piper Sandler assumed coverage on shares of AnaptysBio in a research report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective on the stock. JPMorgan Chase & Co. cut their price target on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, April 1st. Wells Fargo & Company initiated coverage on AnaptysBio in a research report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 target price on the stock. SVB Leerink began coverage on AnaptysBio in a report on Tuesday. They set an “outperform” rating and a $47.00 target price on the stock. Finally, BTIG Research started coverage on AnaptysBio in a research note on Monday, February 26th. They issued a “buy” rating and a $55.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and an average price target of $46.22.

AnaptysBio Trading Up 0.6 %

ANAB stock opened at $21.47 on Tuesday. The stock has a 50-day moving average price of $23.38 and a two-hundred day moving average price of $20.55. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $27.50. The stock has a market cap of $574.54 million, a PE ratio of -3.53 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.74) by $0.15. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. The company had revenue of $9.01 million during the quarter, compared to analysts’ expectations of $3.28 million. On average, analysts forecast that AnaptysBio will post -6.25 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the transaction, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at approximately $17,132,541.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Eric J. Loumeau sold 5,000 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Daniel Faga sold 145,940 shares of the stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the transaction, the chief executive officer now directly owns 752,087 shares in the company, valued at $17,132,541.86. The disclosure for this sale can be found here. Insiders sold a total of 157,005 shares of company stock valued at $3,586,199 over the last three months. Insiders own 35.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently made changes to their positions in the company. Fisher Asset Management LLC lifted its holdings in AnaptysBio by 0.7% during the 4th quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock worth $1,524,000 after purchasing an additional 500 shares during the last quarter. Ensign Peak Advisors Inc increased its position in AnaptysBio by 1.1% during the 1st quarter. Ensign Peak Advisors Inc now owns 45,342 shares of the biotechnology company’s stock worth $1,122,000 after buying an additional 510 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of AnaptysBio by 0.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 149,386 shares of the biotechnology company’s stock worth $3,251,000 after buying an additional 555 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of AnaptysBio by 4.5% during the second quarter. California State Teachers Retirement System now owns 23,523 shares of the biotechnology company’s stock worth $478,000 after buying an additional 1,003 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of AnaptysBio by 6.6% in the fourth quarter. UBS Group AG now owns 18,742 shares of the biotechnology company’s stock valued at $401,000 after acquiring an additional 1,156 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.